Scisparc

Scisparc P/B

The P/B (Price-to-Book Ratio) of Scisparc (SPRC) as of Nov 21, 2026 is 0.62. In the previous year, P/B (Price-to-Book Ratio) was 0.32 — a change of 92.36% (higher).

P/B

0.62

YoY

92.36%

Last updated:

P/B (Price-to-Book Ratio) of Scisparc is 2025 0.62 . P/B (Price-to-Book Ratio) of Scisparc was 2024 0.32 . It decreases by 92.36% higher compared to the previous year.

The Scisparc P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
14.24 USD
Jan 1, 2019
188.23 USD
Jan 1, 2020
1.84 USD
Jan 1, 2021
0.32 USD
Jan 1, 2022
0.41 USD
Jan 1, 2023
0.35 USD
Jan 1, 2024
0.32 USD
Jan 1, 2025
0.62 USD
The Scisparc P/B history
YEARP/BYoY
0.62+92.36%
0.32-6.62%
0.35-15.30%
0.41+26.24%
0.32-82.43%
1.84-99.02%
188.23+1,221.43%
14.24+4,293.51%
0.32-92.95%
4.60+128.74%
2.01-102.80%
-71.76—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

P/B (Price-to-Book Ratio) of Scisparc is 0.62 in 2025.

P/B (Price-to-Book Ratio) of Scisparc changed from 0.32 to 0.62, representing a 92.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Scisparc since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Scisparc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Scisparc

All Key Metrics — Scisparc